What Recent Patent Broker Sales Tell Us About the 2025–2026 Market

Every year clients ask me the same question in different wrappers: is now a good time to sell? The honest answer depends less on where the market is pointed and more on what you own, who would infringe it and whether you can price it like a buyer rather than a seller. That said, the latest broker data gives us a clearer read than usual on what is actually moving through the secondary market.

The headline number: $158M, again

Richardson Oliver Insights pegged the 2024 brokered patent market at roughly $158 million in closed transactions, essentially flat with 2022 and 2023. That number surprises a lot of people, especially first time sellers who assume broker driven deals are a multibillion dollar pool. They are not. The brokered market is a narrow slice of overall patent transfers and it has settled into a steady rhythm at this level for about the last three years.

Two things worth knowing about that $158M: first, only about one in five packages brought to market actually closes which is a metric every client should know when weighing whether to list. Second, cumulative asking prices tracked since 2012 now exceed $38 billion so the gap between what sellers want and what buyers pay remains enormous. Asking prices tell you about seller psychology. Closing prices tell you about the market.

Who is buying

NPEs continue to take a meaningful share of what moves. AST's Q3 2025 data showed NPEs accounting for 29% of acquisitions with 17 new NPE entities entering the market that quarter alone. Several of those new entities filed litigation within weeks of closing and a notable share of the litigated assets had been shopped to defensive aggregators first. That sequence, list with a broker, get passed over by operating companies, sell to a new NPE, litigate shortly after, is now common enough that operating company buyers treat early visibility as a defensive strategy rather than a procurement one.

Operating companies still buy and on an asset count basis they often buy more than NPEs. But they buy differently. They tend to be selective, slow and focused on assets that plug a specific defensive or cross licensing gap. If you are selling a portfolio that has not been cleanly mapped against a corporate buyer's product line, you are unlikely to close with one.

Who is selling, and why it matters for pricing

Most sellers in the brokered market are operating companies divesting non-core assets, along with universities, individual inventors and smaller NPEs rotating portfolios. Academic participation hit 24% of Q1 2025 transactions with the Chinese Academy of Sciences leading. Some of those university originated assets have already shown up in litigation against names like Fortinet, CrowdStrike and HPE shortly after transfer. That matters because when you price a patent today, the realistic buyer universe includes entities whose business model requires the asset to be enforceable not just interesting.

This is where I spend a lot of time with valuation clients. The income-method value of a patent is frequently very different from what a broker could actually sell it for. The market does not pay for theoretical royalty streams. It pays for demonstrable infringement by well resourced targets, claims that survive an IPR and a price that accounts for litigation cost and time-to-money. A CPVA grounded valuation that ignores those discounts is a number on paper not a price.

What is actually moving

High tech dominates. Semiconductors, electronics, lighting and computing systems accounted for roughly 59% of transacted assets in Q3 2025. The top five deals alone took 25% of transacted assets. That is typical for this market, where a handful of large lots skew the volume. Recent examples include Equip IP Management, a new NPE, acquiring 101 semiconductor assets from AUO and GE Vernova picking up 81 industrial assets from Cummins. Both illustrate the two dominant buyer profiles: a freshly formed monetization vehicle and a strategic operator filling a portfolio gap.

The backdrop that is changing prices

A few structural shifts are worth flagging, because they are quietly repricing the whole asset class:

IPR institution rates collapsed after USPTO Director John Squires took personal control of institution decisions in October 2025. Early data showed institutions dropping to roughly 4% of fully processed petitions. If that holds, the risk discount sophisticated buyers apply for PTAB invalidation shrinks which is directly accretive to patent prices. It is being litigated so I would not bet the portfolio on it but it is probably the most important pricing variable right now.

The Federal Circuit's en banc EcoFactor v. Google decision in May 2025 tightened how damages experts can build royalty analyses from prior settlement agreements. That has made damages cases harder for plaintiffs and changes how buyers model enforceable value.

Damages awards through the first half of 2025 exceeded $1.9 billion across 21 major cases including the $634 million Masimo v. Apple verdict on pulse oximetry. Big awards do not float every boat but they do refresh buyer appetite for well charted assets in adjacent technology areas.

The pharmaceutical patent cliff, with $170B to $236B in revenue exposure through 2030–2032, is driving a separate and much larger wave of patent adjacent M&A. That is not the brokered market but it is changing who has cash and urgency.

What I tell clients thinking about selling

Three things, consistently.

First, get honest about the one in five close rate before you list. The patents that sell share common traits: clean chain of title, a credible infringement story mapped to specific product features, claims that read on current implementations and pricing that reflects litigation economics. If your portfolio is missing any of those, fix it before you go to market or adjust your price expectation sharply downward.

Second, do the evidence of use work up front. Sellers who come to market with claim charts and EOU materials close more deals and they close them faster. This is not optional anymore. Buyers have too many options and too little time to do the mapping themselves. Plug for my work, the infringement search report that MRT Patents offers with EOU and claim charts is always valuable to clients to understand the products on that market that their claim charts map to.

Third, think carefully about who you are actually willing to sell to. Selling to an NPE is a legitimate outcome and often the highest price outcome. But it has reputational and customer relationship implications that some operating company sellers do not fully weigh until the assertion letters go out to their former peers. That conversation belongs at the front of the process not the end.

Where this leaves us going into the rest of 2026

The brokered market is stable, selective and modestly more favorable to sellers than it was a few years ago mostly because of the PTAB shift and steady NPE demand. It is not a hot market. It is a market where good patents priced correctly will close and everything else will sit. For clients considering a sale, that is actually useful clarity. It means the work of preparing a portfolio properly, valuing it honestly and pricing it realistically gets rewarded. Hope does not.

If you are weighing a sale, a refresh of your valuation or an infringement-mapping exercise to decide whether your assets are listable, that is exactly the kind of work we do at MRT Patents. Happy to talk through it.